435 related articles for article (PubMed ID: 22541618)
61. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview.
Hassani M; Koenderman L
Allergy; 2018 Oct; 73(10):1979-1988. PubMed ID: 29611207
[TBL] [Abstract][Full Text] [Related]
62. Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.
Menzella F; Lusuardi M; Galeone C; Taddei S; Zucchi L
J Asthma Allergy; 2015; 8():105-14. PubMed ID: 26504401
[TBL] [Abstract][Full Text] [Related]
63. Oral corticosteroid sparing effects of anti-IL5/ anti-IL5 receptor treatment after 2 years of treatment.
Bjerrum AS; Skjold T; Schmid JM
Respir Med; 2021 Jan; 176():106260. PubMed ID: 33264712
[TBL] [Abstract][Full Text] [Related]
64. Novel targeted therapies for eosinophilic disorders.
Wechsler ME; Fulkerson PC; Bochner BS; Gauvreau GM; Gleich GJ; Henkel T; Kolbeck R; Mathur SK; Ortega H; Patel J; Prussin C; Renzi P; Rothenberg ME; Roufosse F; Simon D; Simon HU; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2012 Sep; 130(3):563-71. PubMed ID: 22935585
[TBL] [Abstract][Full Text] [Related]
65. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
66. Mepolizumab for eosinophilic severe asthma: recent studies.
Robinson DS; Kariyawasam HH
Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
[TBL] [Abstract][Full Text] [Related]
67. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
[TBL] [Abstract][Full Text] [Related]
68. Reslizumab for pediatric eosinophilic esophagitis.
Walsh GM
Immunotherapy; 2010 Jul; 2(4):461-5. PubMed ID: 20636000
[TBL] [Abstract][Full Text] [Related]
69. Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.
Shrimanker R; Pavord ID
BioDrugs; 2017 Apr; 31(2):93-103. PubMed ID: 28364396
[TBL] [Abstract][Full Text] [Related]
70. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
[TBL] [Abstract][Full Text] [Related]
71. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
Stein ML; Villanueva JM; Buckmeier BK; Yamada Y; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2008 Jun; 121(6):1473-83, 1483.e1-4. PubMed ID: 18410960
[TBL] [Abstract][Full Text] [Related]
72. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.
Matucci A; Maggi E; Vultaggio A
Respir Med; 2019; 160():105819. PubMed ID: 31734469
[TBL] [Abstract][Full Text] [Related]
73. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):1-8. PubMed ID: 31136278
[TBL] [Abstract][Full Text] [Related]
74. Mepolizumab treatment for asthma.
Robinson DS
Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
[TBL] [Abstract][Full Text] [Related]
75. Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease.
Devos R; Plaetinck G; Cornelis S; Guisez Y; Van der Heyden J; Tavernier J
J Leukoc Biol; 1995 Jun; 57(6):813-9. PubMed ID: 7790761
[TBL] [Abstract][Full Text] [Related]
76. Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
Varricchi G; Senna G; Loffredo S; Bagnasco D; Ferrando M; Canonica GW
Front Immunol; 2017; 8():242. PubMed ID: 28344579
[TBL] [Abstract][Full Text] [Related]
77. Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.
Bagnasco D; Ferrando M; Caminati M; Bragantini A; Puggioni F; Varricchi G; Passalacqua G; Canonica GW
Drug Saf; 2017 Jul; 40(7):559-570. PubMed ID: 28321782
[TBL] [Abstract][Full Text] [Related]
78. IL-5 and eosinophilia.
Takatsu K; Nakajima H
Curr Opin Immunol; 2008 Jun; 20(3):288-94. PubMed ID: 18511250
[TBL] [Abstract][Full Text] [Related]
79. Update on reslizumab for eosinophilic asthma.
Cardet JC; Israel E
Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
[TBL] [Abstract][Full Text] [Related]
80. [Severe refractory eosinophilic asthma].
Jäger-Becker D
MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
